Efficacy of targeted therapy for lung cancer patients included in IMPRESS-Norway, and precision cancer medicine in hard-to-treat rare cancers in the MATRIX-RARE study.
Romero-Becerra R, Zhao Z, Nebdal D, Müller E, Bergholtz H, Norum JH, Aittokallio T(2025) Improved analysis of in vivo drug combination experiments with a comprehensive statistical framework and web-tool Nat Commun, 16(1), 10151 DOI 10.1038/s41467-025-65218-9, PubMed 41258298
Horndalsveen H, Haakensen VD, Madebo T, Grønberg BH, Halvorsen TO, Koivunen J, Oselin K, Cicenas S, Helbekkmo N, Aanerud M, Ahvonen J, Silvoniemi M, Bjaanæs MM, Farooqi S, Nebdal D, Dalsgaard AM, Danielsen BK, Børve M, Dalen TS, Öjlert ÅK, Helland Å(2025) Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab Front Oncol, 15, 1681420 DOI 10.3389/fonc.2025.1681420, PubMed 41199847
Førde D, Kilvær T, Pedersen MI, Lombardi AP, D'arsiè I, Paulsen EE, Busund LR, Rakaee M, Dønnem T, Andersen S(2025) Prognostic impact of miR-17-5p and miR-20a-5p in NSCLC diverge in subgroups according to lymph node status Front Oncol, 15, 1606933 DOI 10.3389/fonc.2025.1606933, PubMed 41079079
